Acrobiosystems for English
icon_bulk_orderAchat groupé/Commande rapide
user
  1. Tableau de bord
  2. Mon profil
  3. Mon adresse
  4. Mes commandes
  5. Adhésion à Acro
Connexion Inscription
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
Il n'y a pas de produit dans le panier !
Mon panier|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > LILRB2

LILRB2

Brief Information

Name:Leukocyte immunoglobulin-like receptor subfamily B member 2
Target Synonym:Leukocyte immunoglobulin-like receptor 2,CD85 antigen-like family member D,Immunoglobulin-like transcript 4,ILT-4,Monocyte/macrophage immunoglobulin-like receptor 10,MIR-10,CD_antigen: CD85d,LILRB2,Leukocyte Immunoglobulin Like Receptor B2,Leucocyte Ig-Like Receptor B2,MIR10,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 2,Ig-Like Transcript 4,Myeloid Inhibitory Receptor 10,CD85d Antigen,ILT4,LIR2,CD85d,LIR-2,LIRB2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Phase 2 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
LILRB2 mAb - 01 PCC Solid Tumor Solid tumor

Product ListCompare or Buy

Product> Filter Results
Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
LI2-H5253 Human Human LILRB2 / CD85d / ILT4 Protein, Fc Tag (MALS verified)
LI2-H5253-structure
LI2-H5253-sds
LI2-H82E7 Human Biotinylated Human LILRB2 / CD85d / ILT4 Protein, His,Avitag™ (MALS verified)
LI2-H82E7-structure
LI2-H82E7-sds
LI2-C52H3 Cynomolgus Cynomolgus LILRB2 / CD85d / ILT4 Protein, His Tag
LI2-C52H3-structure
LI2-C52H3-sds
LI2-C82E3 Cynomolgus Biotinylated Cynomolgus LILRB2 / CD85d / ILT4 Protein, His,Avitag™
LI2-C82E3-structure
LI2-C82E3-sds
LI2-H82F5 Human Biotinylated Human LILRB2 / CD85d / ILT4 Protein, Fc,Avitag™ (MALS verified)
LI2-H82F5-structure
LI2-H82F5-sds
LI2-H5220 Human Human LILRB2 / CD85d / ILT4 Protein, His Tag (MALS verified)
LI2-H5220-structure
LI2-H5220-sds
ACRO Quality

Part of Bioactivity data

LI2-H82E7-ELISA
LILRB2 ELISA

Immobilized Anti-LILRB2 Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Biotinylated Human LILRB2 Protein, His,Avitag (Cat. No. LI2-H82E7) with a linear range of 0.3-20 ng/mL (QC tested).

Protocol
LI2-H5253-MALS-HPLC
LILRB2 MALS images

The purity of Human LILRB2, Fc Tag (Cat. No. LI2-H5253) is more than 95% and the molecular weight of this protein is around 160-190 kDa verified by SEC-MALS.

Synonym Name

LILRB2,ILT4,LIR2,MIR10,CD85d

Background

Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Clinical and Translational Updates

Related Molecule

ANGPTL7

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Polzastobart JTX-8064 Phase 2 Clinical Jounce Therapeutics Inc Neoplasms Details
IO-108 IO-108 Phase 2 Clinical Yiming Biomedical Technology (Hangzhou) Co Ltd Solid tumours; Liver Neoplasms Details
MK-4830 MK-4830 Phase 2 Clinical Agenus Inc Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Ovarian Epithelial; uterine serous carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details
OR-502 OR502; OR-502 Phase 2 Clinical OncoResponse Inc Solid tumours; Ovarian Neoplasms; Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis Details
NGM-707 NGM-707 Phase 2 Clinical Merck & Co, Ngm Biopharmaceuticals Inc Ovarian Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Glioblastoma; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma Details
SPX-303 SPX-303 Phase 1 Clinical SparX Biopharmaceutical Corp Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck Details
BMS-986406 BMS-986406 Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
CDX-585 CDX-585 Phase 1 Clinical Boaoxin Biotechnology(Nanjing) Co Ltd, Celldex Therapeutics Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung Details
ES-009 ES-009 Phase 1 Clinical Elpiscience (Shanghai) Biopharma Ltd Solid tumours; Neoplasms Details
Polzastobart JTX-8064 Phase 2 Clinical Jounce Therapeutics Inc Neoplasms Details
IO-108 IO-108 Phase 2 Clinical Yiming Biomedical Technology (Hangzhou) Co Ltd Solid tumours; Liver Neoplasms Details
MK-4830 MK-4830 Phase 2 Clinical Agenus Inc Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Ovarian Epithelial; uterine serous carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details
OR-502 OR502; OR-502 Phase 2 Clinical OncoResponse Inc Solid tumours; Ovarian Neoplasms; Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis Details
NGM-707 NGM-707 Phase 2 Clinical Merck & Co, Ngm Biopharmaceuticals Inc Ovarian Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Glioblastoma; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma Details
SPX-303 SPX-303 Phase 1 Clinical SparX Biopharmaceutical Corp Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck Details
BMS-986406 BMS-986406 Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
CDX-585 CDX-585 Phase 1 Clinical Boaoxin Biotechnology(Nanjing) Co Ltd, Celldex Therapeutics Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung Details
ES-009 ES-009 Phase 1 Clinical Elpiscience (Shanghai) Biopharma Ltd Solid tumours; Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us

Germany+49 800 0826645

United Kingdom+44 808 281 3436

Netherlands+31 800 0224992

Switzerland+41 800 040 012

France+33 800 90 78 85

Sweden+46 20 12 76 94

Denmark+45 80 83 07 62

Belgium+32 800 27 125

Email
E-Mail
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland
linkedin twitter facebook youtube

Laisser un message

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap